Ratings STAAR Surgical Company Deutsche Boerse AG

Equities

SR3

US8523123052

Market Closed - Deutsche Boerse AG Other stock markets 11:33:25 28/06/2024 am IST			5-day change	1st Jan Change
43.48 ^EUR	+2.74%		+16.82%	+50.50%

21/06	STAAR Surgical Company Provides Information to the Shareholders	CI
12/06	Transcript : STAAR Surgical Company Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:00 AM

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Over the past four months, analysts' average price target has been revised upwards significantly.
Analyst opinion has improved significantly over the past four months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's "enterprise value to sales" ratio is among the highest in the world.
The company appears highly valued given the size of its balance sheet.
The company is highly valued given the cash flows generated by its activity.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
STAAR SURGICAL COMPANY	+50.50%	2.34B	-
ABBOTT LABORATORIES	-5.60%	181B	C+
MEDTRONIC PLC	-4.45%	101B	C
BECTON, DICKINSON AND COMPANY	-4.15%	67.54B	A
DEXCOM, INC.	-8.63%	45.09B	B-
CENCORA, INC.	+9.70%	44.37B	B-
HOYA CORPORATION	+6.13%	40.7B	B+
METTLER-TOLEDO INTERNATIONAL, INC.	+15.22%	29.85B	B
TERUMO CORPORATION	+14.80%	24.49B	A-
WEST PHARMACEUTICAL SERVICES, INC.	-6.46%	23.99B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes